Gestalt Diagnostics, Spokane, Wash, a pathology laboratory software company, and Flagship Biosciences, Westminster, Colo, a tissue analysis service company, are partnering to develop an integrated workflow solution for pathologists who use Flagship’s image analysis services for PD-L1 testing. The goal is to streamline the diagnostic process by adding Flagship’s computational services to Gestalt’s digital pathology solution, PathFlow.

Lisa-Jean Clifford, Gestalt Diagnostics.

Lisa-Jean Clifford, Gestalt Diagnostics.

Users of Gestalt’s PathFlow system will be able to request the PD-L1 cell surface receptor image analysis service directly, from within the interface. A consistent PD-L1 report and images are returned and loaded into the case file for final review.

“Our relationship with Flagship Biosciences, and the resulting automated and streamlined workflow for PD-L1 cases, is another step forward in our digital platform,” says Lisa-Jean Clifford, COO and chief strategy officer at Gestalt. “This new relationship is giving pathologists access to automation and tools that will continue to increase their efficiency, minimizing the manual steps in their casework. We are pleased to partner with Flagship Biosciences to integrate their machine learning and artificial intelligence tools to provide cancer marker detection.”

Our goal is to provide a more streamlined workflow for pathologists, as well as to provide more insight for oncologists through our computational services,” says Trevor Johnson, CEO of Flagship. “We’re pleased to be partnering with Gestalt to advance the state of diagnostics through the use of image analysis.”

For more information, visit Flagship Biosciences and Gestalt Diagnostics.